A National Spinal Muscular Atrophy Registry for Real-World Evidence.

Area of Science:

• Neurology
• Rare Diseases
• Clinical Research

Background:

• Spinal muscular atrophy (SMA) is a rare, severe disease affecting all populations.
• Nusinersen is the first disease-modifying therapy for SMA, approved based on limited pediatric trial data.
• Real-world data is crucial for monitoring rare adverse events and effectiveness in broader patient populations.

Purpose of the Study:

• To expand the Canadian Neuromuscular Disease Registry (CNDR) SMA dataset for post-marketing surveillance.
• To evaluate the safety and effectiveness of novel SMA therapies in a real-world setting.
• To gather practical patient outcome information not available from clinical trials.

Main Methods:

• A longitudinal, prospective, observational study of Canadian SMA patients.
• Development of a consensus-based, expanded dataset capturing therapy effectiveness and safety.
• Inclusion of SMA patients regardless of therapeutic status in a multicenter approach.

Main Results:

• The expanded dataset includes standardized outcome measures for therapy effectiveness and safety.
• Data collection is aligned with global datasets to foster international collaboration.
• Prospective outcome studies and data analyses are independent of funding sources.

Conclusions:

• Prospective data will yield insights into the safety and effectiveness of SMA therapies post-approval.
• This real-world evidence is vital for enhancing patient care and optimizing therapy access.
• The registry aims to inform improvements in the management of spinal muscular atrophy.